Please login to the form below

Not currently logged in
Email:
Password:

Cellectis

This page shows the latest Cellectis news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

The latest from pharma, biotech and healthcare. Cellectis gains senior scientist from Novartis. ... on the development and long-term strategic planning for Cellectis’ innovative product portfolio,” said Dr.

Latest news

  • Sangamo bulks up in cell therapy with TxCell acquisition Sangamo bulks up in cell therapy with TxCell acquisition

    Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’ favoured TALENS.

  • Gilead signs $3bn-plus gene-editing deal with Sangamo Gilead signs $3bn-plus gene-editing deal with Sangamo

    The deal with Sangamo means rivals in the CAR-T category such asand off-the-shelf specialist Cellectis won’t be able to use the ZFN technology in their own ... Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’ favoured

  • Cellectis floored by patient death in CAR-T trial Cellectis floored by patient death in CAR-T trial

    It may be that the FDA will exercise greater caution in Cellectis' case. ... UCART19 is partnered with Servier and Pfizer. Cellectis' Nasdaq-listed shares are currently trading at around $25, down from more than $32 ahead of the patient death announcement

  • Servier cleared to start US trials CAR-T therapy Servier cleared to start US trials CAR-T therapy

    The French pharma company entered the race to develop chimeric antigen receptor therapies (CAR-T) for cancer after it acquired exclusive rights to UCART19 from Cellectis in 2015. ... Cellectis specialises in the development of ‘off-the-shelf’ CAR-T

  • Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial

    Cellectis has been given the go-ahead by the FDA to start trials of its CAR-T immunotherapy UCART123 in patients with two haematological cancers. ... This is not the first time that one of Cellectis' CAR-T candidates has been tested in patients however.

More from news
Approximately 8 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.

  • Pharma deals in May 2015 Pharma deals in May 2015

    Following the collaboration announced in June 2014 with Cellectis, the rumours are now going around that Pfizer may be planning an acquisition with an estimated price tag of $1.6bn.

  • Pharma deals in March 2015 Pharma deals in March 2015

    Also Evaluate reports a cautious approach by big pharma. Novartis, J&J and Pfizer (via a deal with Cellectis) are in the go-kart race but other companies such as Merck

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    350. Medreich/ Meiji Seika. Company acquisition. India-based manufacturing company. 290. Cellectis/ Pfizer.

  • Pharma deals during June 2014 Pharma deals during June 2014

    Cellectis has reserved 12 other targets and Pfizer will provide preclinical development assistance for four of these. ... easily. Cellectis plans to open a research site in the US to work more closely with Pfizer.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics